Symbol="INMB"
AssetType="Common Stock"
Name="INmune Bio Inc"
Description="INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California."
CIK="1711754"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="1200 PROSPECT STREET, SUITE 525, LA JOLLA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="170666000"
EBITDA="None"
PERatio="None"
PEGRatio="None"
BookValue="3.081"
DividendPerShare="0"
DividendYield="0"
EPS="-1.56"
RevenuePerShareTTM="0.014"
ProfitMargin="0"
OperatingMarginTTM="-103.64"
ReturnOnAssetsTTM="-0.192"
ReturnOnEquityTTM="-0.411"
RevenueTTM="249000"
GrossProfitTTM="374000"
DilutedEPSTTM="-1.56"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.767"
AnalystTargetPrice="17.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="306.31"
PriceToBookRatio="2.155"
EVToRevenue="216.5"
EVToEBITDA="-3.247"
Beta="1.962"
num_52WeekHigh="10.75"
num_52WeekLow="5.75"
num_50DayMovingAverage="8.23"
num_200DayMovingAverage="7.71"
SharesOutstanding="17946000"
DividendDate="None"
ExDividendDate="None"
symbol="INMB"
open="8.60"
high="9.70"
low="8.57"
price="9.51"
volume="47727.00"
latest_trading_day="2023-07-07"
previous_close="8.71"
change="0.80"
change_percent="9.1848%"
aroon_positive_momentum_days="50"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="50"
Volume_recent_avg="48657"
Change_recent_avg="-0.02"
Delta_recent_avg="0.56"
Variance_recent_avg="0.28"
Change_ratio_recent_avg="-0.36"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="50"
Aroon_momentum_negative="50"
image_negative_thumbnail_id_1="1105"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0138.jpeg"
image_negative_thumbnail_id_2="1137"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0170.jpeg"
image_neutral_thumbnail_id_1="557"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_neutral_thumbnail_id_2="569"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_positive_thumbnail_id_1="611"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0097.jpeg"
image_positive_thumbnail_id_2="1001"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0163.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1176"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
